Belinostat, a potent HDACi, exerts antileukemic effect in human acute promyelocytic leukemia cells via chromatin remodelling

Autor: Ruta Navakauskiene, Giedre Valiuliene, Ieva Stirblyte, Mindaugas Valius, Dovile Cicenaite, Algirdas Kaupinis

Publikováno v: Journal of cellular and molecular medicine, Oxford : Wiley-Blackwell Publishing Ltd., 2015, vol. 19, no. 7, p. 1742-1755
Journal of Cellular and Molecular Medicine

Epigenetic changes play a significant role in leukaemia pathogenesis, therefore histone deacetylases (HDACis) are widely accepted as an attractive strategy for acute promyelocytic leukaemia (APL) treatment. Belinostat (Bel, PXD101), a hydroxamate-typ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96f0e5cd25dc620cf3e762f89149878d
https://repository.vu.lt/VU:ELABAPDB13940727&prefLang=en_US